Who Owns Covetrus Company?

Covetrus Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who owns Covetrus now?

In October 2022 private equity firms Clayton, Dubilier & Rice and TPG Capital bought Covetrus for about $4.0 billion equity value, taking it private and shifting control from public shareholders to PE owners. That change reshaped priorities across software, supply chain, and prescriptions.

Covetrus began in 2019 from Henry Schein’s Animal Health spin-off merged with Vets First Choice; by 2021 it served tens of thousands of clinics with ~$4.6 billion revenue. Ownership now rests with CD&R and TPG, influencing strategy, investments, and governance.

Explore a product analysis: Covetrus Porter's Five Forces Analysis

Founders and Early Ownership of Covetrus trace back to Vets First Choice, founded in 2010 in Portland, Maine by Benjamin Shaw and David E. Shaw. The founders and early employees initially held private equity stakes while venture and growth investors joined across the 2010s, setting up typical vesting and ROFR/drag/tag protections.

Founding team

Benjamin Shaw led product and CEO roles; David E. Shaw brought life‑sciences entrepreneurship experience from IDEXX Laboratories.

Initial ownership

Vets First Choice began as a privately held company owned by founders and early employees with venture participation over successive rounds.

Governance

Founder-led management and board representation reflected the company’s software- and data-led strategic vision for veterinary workflows.

Financing structure

Early financing included venture and growth investors; shareholder agreements used standard vesting, ROFR and drag/tag clauses.

Founder dilution

At the 2019 Covetrus formation, VFC shareholders collectively received 37% of the combined company, indicating significant but partial dilution of founder stakes.

Liquidity events

Any founder liquidity before 2019 occurred via secondary sales in private rounds; no public records show major cap table disputes before the merger.

Founders maintained strategic influence through management roles and board seats up to the Covetrus combination, aligning with the ownership and governance norms seen in venture-backed healthcare and pet‑care technology firms.

Key facts and implications

Relevant ownership points for investors researching who owns Covetrus and Covetrus ownership history.

• Vets First Choice founded in 2010 by Benjamin Shaw and David E. Shaw in Portland, Maine
• VFC shareholders received an aggregate 37% of Covetrus at the 2019 formation
• Early capital rounds included venture and growth investors with standard private‑company shareholder protections
• No public record of material founder cap‑table disputes prior to the 2019 combination

For context on market positioning and stakeholder targeting that influenced founder strategy, see Target Market of Covetrus

Covetrus SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Key events reshaping Covetrus ownership include the February 7, 2019 spin‑merge creating the public CVET, institutional accumulation and insider holdings during 2019–2022, and the October 13, 2022 take‑private by CD&R and TPG that concentrated control and reoriented strategic priorities.

Post‑transaction (2023–2025) Covetrus ownership is private, led by funds affiliated with Clayton, Dubilier & Rice and TPG, with executive rollover equity and incentive plans but no public float or government parent; strategic emphasis shifted to software‑led growth and margin expansion funded by private capital.

Ownership milestones and current stakeholders

Major ownership phases: spin‑merge IPO, institutional public ownership, and private equity control. Current structure is concentrated private ownership focused on long‑term transformation.

• Who owns Covetrus: primarily CD&R and TPG funds as of 2025
• Covetrus ownership breakdown by shareholder type: concentrated private equity with management rollover (no public institutions post‑deal)
• Is Covetrus privately owned or public: privately owned since Oct 13, 2022
• Further reading: Brief History of Covetrus

Covetrus PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

Covetrus's board following the 2024 take‑private transaction is dominated by representatives appointed by CD&R and TPG alongside the CEO and a small number of independent directors with industry, software and supply‑chain experience; governance now reflects sponsor‑driven oversight rather than public shareholder voting.

Post‑transaction voting authority is exercised through private equity sponsor agreements and equity ownership (majority held by CD&R and TPG), not via a dual‑class share structure; disclosed governance focuses on KPIs, cash generation and the technology roadmap, and there have been no widely reported proxy contests since privatization.

Board composition and voting dynamics

The board combines sponsor appointees, executive leadership and independent directors to align operational execution with sponsor value‑creation plans.

• Control derives from majority economic ownership and board designation rights in sponsor agreements
• No public dual‑class or golden‑share structure has been disclosed post‑take‑private
• Governance targets include operational KPIs, cash flow and tech roadmap milestones
• For historical governance context and company values see Mission, Vision & Core Values of Covetrus

Covetrus Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Since the October 2022 privatization, Covetrus ownership concentrated with private equity sponsors, shifting away from public index and ETF holders and enabling a strategic focus on software, pharmacy and practice-management consolidation under sponsor stewardship.

In a private structure, public buybacks/secondaries are not public; sponsors typically use internal recapitalizations to refine cap tables as performance and interest rates evolve, supporting a 3–6 year exit horizon tied to EBITDA growth and market multiples.

Ownership concentration since 2022

CD&R and TPG control the capital structure post-privatization, eliminating typical public shareholder pressures and enabling faster strategic pivots.

Operational focus and bolt-on strategy

Management has prioritized SKU rationalization and platform upgrades while targeting tuck-in acquisitions in practice-management and pharmacy workflow tools.

Market dynamics supporting sponsors

The global animal health market is growing mid-single to high-single digits annually; veterinary software and e-commerce/pharmacy often post high single to low double-digit CAGRs, underpinning a software-led margin mix shift.

Exit pathway expectations

No public signals of imminent re-IPO; typical sponsor exits include strategic sale or relisting over a 3–6 year window, dependent on leverage, EBITDA growth and market multiples.

For further context on strategic positioning and marketing implications tied to ownership shifts, see Marketing Strategy of Covetrus

Covetrus Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔